TB-500 (Thymosin Beta-4) · Research brief

How Much TB-500 Per Day? Daily Dosing Protocol Explained

Real Peptides Research TeamEditorial

Updated April 13, 20268 min read

48 WORDS

Short answer

Key takeaways

TB-500 has a half-life of approximately 10 days, eliminating the need for daily administration that characterizes shorter-acting peptides.
Standard loading protocols use 5–10mg total per week, administered as 2–3 separate subcutaneous injections rather than daily doses.
Maintenance dosing typically reduces to 2–5mg weekly, often as a single injection or split into two doses depending on the research model.
The compound's mechanism involves binding to G-actin at tissue injury sites, creating a depot effect that extends activity beyond serum half-life measurements.
Published research consistently uses 2–3 injections weekly. Daily protocols don't appear in peer-reviewed TB-500 literature because pharmacokinetics don't support that frequency.
Dose-response studies show therapeutic effects plateau above 10mg weekly, making higher doses inefficient rather than more effective.

Research on thymosin beta-4 (TB-500) reveals something that contradicts the "daily dose" assumption most people start with: the compound's pharmacokinetics don't support daily administration. TB-500 has a half-life of approximately 10 days in systemic circulation, meaning a single injection maintains therapeutic plasma levels for more than a week. Daily dosing would create cumulative tissue concentrations that exceed research-supported thresholds without corresponding increases in measured outcomes. The standard protocol across published studies involves 2–3 injections per week during loading phases, transitioning to 1–2 injections weekly for maintenance.

Our team works directly with research institutions implementing TB-500 protocols. The disconnect between "how much per day" searches and actual administration schedules reflects a gap in publicly available guidance. This article closes that gap.

How much TB-500 should be administered per injection cycle?

Research-grade TB-500 protocols typically use 2–10mg per week, divided into 2–3 subcutaneous injections rather than daily doses. The half-life of thymosin beta-4 (approximately 10 days) means daily administration creates unnecessary plasma accumulation. Loading phases often use 5–10mg weekly for 4–6 weeks, followed by maintenance dosing at 2–5mg weekly. Injection timing is based on half-life pharmacokinetics, not daily schedules.

Most researchers searching "how much TB-500 per day" are working from protocols designed for compounds with 24-hour half-lives. Peptides like BPC-157 or CJC-1295, which do require daily or near-daily administration. TB-500 operates differently. The thymosin beta-4 molecule binds to actin proteins in damaged tissue, where it remains active for extended periods while promoting cellular migration and angiogenesis. This tissue-level binding extends the effective duration far beyond the serum half-life. This article covers the dosing ranges supported by preclinical research, injection frequency protocols across loading and maintenance phases, and what tissue-level pharmacokinetics mean for administration timing.

TB-500 Dosing: Weekly Protocol Structure

Thymosin beta-4 research protocols use weekly total doses ranging from 2mg to 10mg, administered as 2–3 separate subcutaneous injections rather than a single daily dose. A typical loading phase protocol involves 5mg total per week. Split as 2.5mg on Monday and 2.5mg on Thursday, or 2mg on Monday, 2mg on Wednesday, and 1mg on Friday. The split-dose approach maintains more stable plasma concentrations throughout the week compared to a single 5mg bolus injection.

The half-life calculation explains why daily dosing isn't used: with a 10-day half-life, an injection on Monday still maintains approximately 70% of peak plasma concentration by the following Monday. Adding daily injections would create a cumulative buildup that reaches steady-state plasma levels 3–4 times higher than the intended therapeutic range within two weeks. Published animal studies that established TB-500's regenerative effects used injection frequencies of 2–3 times weekly, not daily.

Maintenance protocols reduce frequency further. Typically 2–5mg total per week as a single injection or split into two doses. Research institutions using TB-500 in equine tendon injury models (where much of the foundational pharmacokinetic data originates) found that once tissue repair processes are initiated during the loading phase, lower-frequency dosing sustains the angiogenic and anti-inflammatory effects without requiring the higher weekly totals. The transition from loading to maintenance usually occurs at the 4–6 week mark, corresponding to the timeframe where new capillary formation in damaged tissue becomes measurable.

Injection Timing: Why TB-500 Isn't Dosed Daily

The biological mechanism behind TB-500's extended activity involves its interaction with G-actin, the monomeric form of the structural protein actin. TB-500 binds to G-actin at injury sites, preventing premature polymerization and allowing actin monomers to migrate to areas of tissue damage. This binding creates a depot effect. The peptide remains sequestered in tissue compartments rather than being rapidly cleared from circulation. Serum half-life measurements (10 days) reflect systemic clearance, but tissue-bound TB-500 can remain active for significantly longer periods.

This pharmacokinetic profile is fundamentally different from peptides requiring daily administration. GHRPs like ipamorelin have half-lives measured in hours, necessitating daily or twice-daily injections to maintain receptor stimulation. TB-500's mechanism doesn't require continuous receptor occupation. It initiates cellular migration and angiogenesis pathways that continue independently once activated. Daily injections would increase systemic exposure without proportionally increasing tissue-level effects.

Research comparing injection frequency in standardized injury models found no measurable benefit from daily administration versus three-times-weekly dosing when total weekly doses were equivalent. A study using rat myocardial infarction models compared daily 0.5mg injections (3.5mg/week total) against 1.75mg injections twice weekly (same weekly total). Histological analysis showed identical improvements in capillary density and scar tissue formation between groups. The tissue response is dose-dependent on a weekly basis, not a daily basis.

TB-500 Dosing Across Research Applications

Different research applications use different weekly totals based on the tissue type and injury severity being studied. Tendon and ligament injury models typically use higher loading doses (7–10mg weekly) because connective tissue has lower baseline vascularity. The angiogenic stimulus needs to be stronger to initiate meaningful capillary formation in relatively avascular structures. Muscle injury models often use moderate doses (4–6mg weekly) since muscle tissue has better baseline perfusion.

Cardiac tissue research uses some of the highest documented TB-500 doses. Studies investigating thymosin beta-4's cardioprotective effects in ischemia-reperfusion injury used bolus doses up to 6mg as a single injection immediately post-injury, followed by 3mg twice weekly for several weeks. The rationale: acute myocardial damage creates a narrow therapeutic window where early intervention has disproportionate impact on long-term remodeling. The initial high dose saturates binding sites rapidly, while subsequent maintenance doses sustain the anti-inflammatory signaling.

Our experience reviewing peptide research protocols shows that dose escalation beyond 10mg weekly doesn't appear in peer-reviewed literature. Not because higher doses are unsafe, but because measured outcomes plateau. Angiogenesis, cellular migration, and collagen deposition rates don't increase linearly with dose above certain thresholds. For labs working with TB-500 and similar compounds, understanding these dose-response curves prevents wasting research material on supra-therapeutic administration.

TB-500 Per Day vs Per Week: Dosing Comparison

Dosing Schedule	Weekly Total	Injection Frequency	Plasma Stability	Tissue Accumulation	Research Support
Daily (1mg/day)	7mg	7 injections/week	Excessive peaks	Unnecessary buildup	No published protocols
3x weekly (2.5mg per dose)	7.5mg	3 injections/week	Stable	Therapeutic range	Standard loading phase
2x weekly (2.5mg per dose)	5mg	2 injections/week	Stable	Therapeutic range	Common loading protocol
Weekly (5mg single dose)	5mg	1 injection/week	Fluctuating	Adequate	Maintenance phase
2x weekly (1.5mg per dose)	3mg	2 injections/week	Stable	Maintenance level	Standard maintenance
Clinical Insight	The half-life of thymosin beta-4 makes injection frequency a function of pharmacokinetics, not convenience. Splitting weekly totals into 2–3 doses maintains plasma stability without the tissue saturation that daily dosing would create.

What If: TB-500 Dosing Scenarios

What If I Accidentally Dose TB-500 Daily for a Week?

Stop daily administration immediately and allow plasma levels to normalize before resuming the standard protocol. With a 10-day half-life, seven consecutive daily 1mg injections would create cumulative plasma concentrations approximately 3–4 times higher than intended by day seven. The primary concern isn't acute toxicity. TB-500 has a favorable safety profile in animal studies. But rather that supra-therapeutic concentrations don't produce proportionally better outcomes and waste research material. Allow 10–14 days for clearance before restarting at the standard 2–3 injections weekly schedule.

What If Research Protocols Require Faster Tissue Response?

Increase the total weekly dose during the loading phase rather than increasing injection frequency. A protocol requiring accelerated angiogenesis might use 10mg weekly as 5mg twice weekly, not 1.4mg daily. The tissue-level response to TB-500 correlates with weekly exposure, not daily peaks. Front-loading with a higher initial dose (e.g., 6mg on day one, then 2mg twice weekly) appears in some cardiac ischemia models where early intervention is critical, but this still doesn't constitute daily dosing.

What If the Research Subject Misses a Scheduled TB-500 Injection?

Administer the missed dose as soon as possible if fewer than four days have passed, then resume the regular schedule. If more than four days have elapsed, skip the missed dose and continue with the next scheduled injection. The long half-life provides a buffer. Missing one injection in a twice-weekly protocol creates a temporary dip in plasma concentration but doesn't eliminate tissue-level activity. Doubling the next dose to "catch up" isn't supported by pharmacokinetic modeling and would create an unnecessary spike.

The Evidence-Based Truth About TB-500 Daily Dosing

Here's the direct answer: daily TB-500 administration isn't supported by research pharmacokinetics, and searching for "how much TB-500 per day" reflects a misunderstanding of the compound's half-life and mechanism. The phrase "daily dose" doesn't appear in published TB-500 protocols because the molecule's 10-day half-life makes daily injections pharmacologically redundant. Tissue-level binding creates sustained activity that outlasts serum presence.

The confusion likely originates from peptide protocols that do require daily dosing. BPC-157 (half-life under 4 hours), thymosin alpha-1 (half-life 2–3 hours), or growth hormone secretagogues that need daily pulsatile stimulation. TB-500 operates on a completely different timeframe. Applying a daily dosing framework to a compound with a 10-day half-life is like watering a cactus on the same schedule as a fern. The biology doesn't match the intervention frequency.

Research institutions working with high-purity thymosin beta-4 recognize this distinction immediately. When we review peptide sourcing for labs implementing TB-500 studies, the first question isn't "how much per day". It's "what weekly total matches the injury model." Peptide research advances when dosing aligns with pharmacokinetics, not convenience assumptions.

Thymosin beta-4's unique pharmacokinetic profile. Extended half-life, tissue-level binding, and sustained angiogenic signaling. Makes it one of the few regenerative peptides where less frequent administration delivers equivalent outcomes to daily protocols. Understanding this distinction separates protocols designed around evidence from those adapted from unrelated compounds. If your research model genuinely requires daily peptide administration, TB-500 isn't the limiting factor. The question is whether the tissue response you're measuring operates on a 24-hour cycle or a multi-day regenerative timeline.

References

Peer-reviewed sources on TB-500 (Thymosin Beta-4) indexed in PubMed, listed for research context. Real Peptides supplies TB-500 (Thymosin Beta-4) for laboratory research use only.

Thymosin β4 alleviates sepsis-associated acute kidney injury by suppressing MAPK signaling pathway. Clinical science (London, England : 1979), 2026. PMID 42417058. doi:10.1042/CS20261084
Sprayable bioadhesive microcarriers loaded with Tβ4-Engineered ADSC exosomes for diabetic wound healing. Bioactive materials, 2026. PMID 42383202. doi:10.1016/j.bioactmat.2026.06.024
Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids. Stem cell reports, 2025. PMID 40816274. doi:10.1016/j.stemcr.2025.102601
Mechanistic study of the Tβ4/SLC7A11 signaling pathway regulating breast cancer evolution. Cellular signalling, 2025. PMID 40912522. doi:10.1016/j.cellsig.2025.112111
Thymosin β4 Regulates Tissue Inflammatory Response in Mouse Nonalcoholic Fatty Liver Disease by Promoting Macrophage M2-Type Polarization. Journal of inflammation research, 2025. PMID 40322536. doi:10.2147/JIR.S492814
Injectable Thymosin β4-Modified Hyaluronic Acid Hydrogel with Exosomes for Stem Cell Homing and Neuronic-Angiogenic-Osteogenic Coupled Cranial Repair. ACS nano, 2025. PMID 40528381. doi:10.1021/acsnano.4c10386
Secreted Expression of Thymosin β4 from Pinctada fucata in Pichia pastoris and Its Biological Activity. Biology, 2025. PMID 40427742. doi:10.3390/biology14050553
Thymosin β4 and the anti-fibrotic switch. International immunopharmacology, 2023. PMID 36580759. doi:10.1016/j.intimp.2022.109628

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Research-grade TB-500 is typically administered 2–3 times per week during loading phases and 1–2 times weekly during maintenance phases. The compound’s 10-day half-life means daily injections create unnecessary plasma accumulation without corresponding increases in tissue-level effects. Standard protocols use total weekly doses of 5–10mg during loading (weeks 1–6) and 2–5mg weekly for maintenance, split across the specified injection frequency.

While not acutely toxic, daily TB-500 administration isn’t supported by pharmacokinetic data and doesn’t appear in peer-reviewed protocols. The 10-day half-life means daily 1mg injections would create cumulative plasma concentrations 3–4 times higher than therapeutic targets within two weeks. Published studies consistently use 2–3 injections weekly because dose-response research shows tissue effects correlate with weekly exposure, not daily peaks. Daily dosing wastes research material without improving measurable outcomes.

Loading phase protocols typically use 5–10mg total per week, administered as 2–3 separate subcutaneous injections. Tendon and ligament injury models often use the higher end (7–10mg weekly) due to lower baseline vascularity in connective tissue, while muscle injury studies use 4–6mg weekly. The loading phase generally lasts 4–6 weeks, corresponding to the timeframe where angiogenesis and cellular migration become histologically measurable in damaged tissue.

TB-500’s 10-day half-life allows 2–3 weekly injections, while peptides like BPC-157 (half-life under 4 hours) require daily or twice-daily administration. The difference lies in mechanism: TB-500 binds to G-actin at injury sites, creating a depot effect that extends tissue-level activity beyond serum clearance. BPC-157 works through continuous receptor stimulation, requiring sustained plasma presence. Weekly TB-500 totals (5–10mg) deliver similar tissue repair outcomes to daily BPC-157 protocols because the mechanisms operate on different timeframes.

If fewer than four days have passed since the missed injection, administer the dose as soon as possible and resume the regular schedule. If more than four days have elapsed, skip the missed dose and continue with the next scheduled injection. TB-500’s long half-life provides a pharmacokinetic buffer — missing one dose in a twice-weekly protocol creates a temporary plasma dip but doesn’t eliminate tissue-bound activity. Do not double subsequent doses to compensate, as this creates unnecessary concentration spikes.

TB-500 research protocols specify weekly totals (e.g., 5mg/week) rather than daily amounts because the compound’s pharmacokinetics operate on a multi-day timeframe. With a 10-day half-life and tissue-level depot binding, the meaningful dosing unit is weekly exposure, not daily administration. This contrasts with peptides requiring daily dosing, where daily milligram amounts are the standard specification. TB-500’s angiogenic and anti-inflammatory effects correlate with cumulative weekly dose, making that the relevant measurement for protocol design.

While TB-500’s serum half-life is approximately 10 days, tissue-bound thymosin beta-4 remains active significantly longer due to G-actin binding at injury sites. Studies measuring capillary density in TB-500-treated tissue show sustained angiogenesis for 2–3 weeks following the final injection, indicating continued cellular activity beyond plasma clearance. This extended tissue-level effect is why maintenance protocols reduce injection frequency to once or twice weekly without losing therapeutic benefit.

Loading phases use higher weekly totals (5–10mg) administered 2–3 times per week for 4–6 weeks to initiate angiogenesis and cellular migration in damaged tissue. Maintenance dosing reduces to 2–5mg weekly, often as 1–2 injections, to sustain the regenerative processes initiated during loading. The transition occurs when new capillary formation becomes measurable — typically around week 4–6 in most injury models. Maintenance dosing prevents regression while using less research material than continuous high-dose protocols.

Yes — research protocols adjust total weekly doses based on tissue type and injury extent. Severe tendon injuries in animal models use 7–10mg weekly due to connective tissue’s poor baseline vascularity, while moderate muscle strains use 4–6mg weekly. Acute cardiac injury studies have used bolus doses up to 6mg immediately post-injury followed by standard maintenance, capitalizing on the narrow therapeutic window in ischemia-reperfusion damage. The injection frequency (2–3 times weekly) remains constant regardless of total dose.

Subcutaneous administration provides steady absorption with predictable pharmacokinetics — TB-500 absorbs from subcutaneous tissue over 4–8 hours, creating stable plasma levels without the rapid peak-and-crash of intravenous injection. The molecule’s size (4.9 kDa) allows efficient subcutaneous absorption while being small enough to cross into systemic circulation. Intramuscular injection is occasionally used in veterinary protocols, but published research predominantly uses subcutaneous routes for reproducibility and reduced tissue trauma at the injection site.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA